**Insights from compassionate use of tocilizumab for COVID-19 to inform appropriate design of randomised controlled trials**

Emma H Baker PhD1,2\*, Kamal Patel MRCP3\*, Jonathan Ball MD4, Sarah Edwards PhD 5, Thomas S Harrison MD1,6, Arvind Kaul PhD7, Mickey Koh MD8, Sanjeev Krishna ScD1,6, 9,10, Susannah Leaver PhD4, Vinodh Kumar MBA2, Daniel M Forton PhD1,3

1. Institute of Infection and Immunity, St George’s, University of London, UK

2. Pharmacy and Medicines Directorate, St George's University Hospitals NHS Foundation Trust, London, UK

3. Department of Gastroenterology and Hepatology, St George's University Hospitals NHS Foundation Trust, London, UK

4. Adult Critical Care Directorate, St George's University Hospitals NHS Foundation Trust, London, UK

5. Department of Science and Technology Studies, University College London, UK

6. Clinical Infection Unit, St George's University Hospitals NHS Foundation Trust, London, UK

7. Department of Rheumatology, St George's University Hospitals NHS Foundation Trust, London, UK

8. Department of Haematology, St George's University Hospitals NHS Foundation Trust, London, UK

9. Institut für Tropenmedizin, Universitätsklinikum Tübingen, Tübingen, Germany

10. Centre de Recherches Médicales de Lambaréné, Gabon

\* Joint first authors

Corresponding author and PI

Daniel Forton

Department of Gastroenterology and Hepatology, St George's University Hospitals NHS Foundation Trust, London, UK

[Daniel.forton@nhs.net](mailto:Daniel.forton@nhs.net)

Tel: +44 208 725 3750

A proportion of patients with progressive COVID-19 display a Cytokine Release Syndrome (CRS) like pattern of hyperinflammation and immune dysregulation in association with respiratory failure. CRS is a form of Systemic Inflammatory Response Syndrome characterised by fever, systemic inflammation, multi-organ failure, and high mortality. In severe COVID-19 [1, 2], there appears to be a unique pattern of hyperinflammatory responses and immune dysregulation, driven by over-production of pro-inflammatory cytokines [3]. In particular, very high levels of interleukin-6 (IL-6) production are associated with low HLA-DR expression and profound lymphopenia.[3] This has fuelled intense interest in the role of IL-6 and other cytokine receptor blockade in COVID-19, using immunomodulatory treatments licensed for conditions such as rheumatoid arthritis and cytokine release syndrome (CRS).

Xu reported a case series of 21 patients treated with intravenous tocilizumab 4-8mg/Kg with lopinavir/ritonavir, interferon- and/or glucocorticoids.[4] There was a rapid clinical improvement and all patients were eventually discharged at an average of 15.1 days after tocilizumab. Although only two of 21 patients were mechanically ventilated, this series triggered initiation of clinical trials to test IL-6 receptor blockade in severe and critical COVID-19. Preliminary results from trials of tocilizumab and sarilumab (press release)[5, 6] are conflicting. In a phase 2 trial of sarilumab 200mg, 400mg or placebo in 457 patients, a positive trend for clinical improvement was seen only in patients classed as critical (requiring high flow oxygen, non-invasive or mechanical ventilation) with a negative trend in patients with milder disease and no overall treatment benefit in a pooled analysis.[5] In contrast, in a French open-label study of 129 non-ICU patients with moderate to severe pneumonia, tocilizumab 8mg/Kg reduced need for ventilation and death by day 14.[6] We note that inclusion criteria for both trials did not include markers of hyperinflammation and outcome measures selected were inconsistent.

In March 2020, we considered the compassionate use of tocilizumab in selected patients, recognising the high COVID-19 mortality[7], and that clinical trials take time to set up and may not report in time to save patients’ lives. Treatment criteria were established, which on the basis of the current literature and multidisciplinary discussion, we felt predicted the best outcomes and adhered to WHO guidelines.[8] Criteria for hyperinflammation were based on emerging data in COVID-19 [1, 9, 10] and an extrapolation of the CRS treatment indications in CAR-T therapy.[11] Patients needed at least three of: D-dimer above upper limit of normal (ULN), rising CRP, ferritin >1000 ng/mL, lactate dehydrogenase (LDH) > ULN, in addition to confirmed SARS-CoV-2, radiographic evidence of pneumonia and increasing oxygen requirement. Patients intubated and ventilated for more than 24 hours (or 48 hours for external referrals) were excluded as we considered that the treatment indication might have passed. Standard tocilizumab contraindications applied[12] in addition to evidence of multi-organ failure, bacterial sepsis, and intubation for reasons other than COVID-19. Oral consent for off label prescription of tocilizumab was obtained from patients or representative, whenever possible.

Seventeen patients were considered for treatment and eleven patients (seven ventilated, four receiving high flow oxygen) received 1-2 doses of tocilizumab 8mg/kg 11.7±4.3 days after first symptoms and 2.8±2.3 days after hospital admission. Over 48 hours after first dose, CRP (half-life 19 hours)[13] fell from 311 (138-332) (median, IQR mg/L) to 110 (58-184) p=0.001 (Figure 1A) and temperatures normalised (Figure 1B). Other hyperinflammation markers: ferritin (long half-life)[14] fell by 44% of baseline over 7 days, LDH was unresponsive to tocilizumab and D-dimers increased. For the whole group, oxygen requirements fell by 60±32% [95% CI 38 to 81] over 1 week, p<0·001. Individual parameters are shown in figures 1C and 1D. The clinical course of patients from day 1 to discharge or death is shown in figure 1E. Nine of the eleven patients were discharged at 14±6 days after treatment. Two intensive care patients died from multiorgan failure, ventilator-associated pneumonia (*Klebsiella aerogenes* in sputum) and refractory respiratory failure.

The good clinical response in this small series suggests that patients might best be selected for IL-6 blockade on the basis of the clinical manifestation of a specific pathophysiology, namely hyperinflammation, rather than by respiratory parameters. Our cohort had higher baseline CRP values compared to those reported by Xu et al[4] (mean 311 versus 65 mg/L) and more patients requiring ventilation (64% versus 10%), yet had similarly good outcomes. Similarly, the French study did not include any patients who required ventilation at baseline. The responders (82%) in our series may have been in a phase of the disease driven mainly by IL-6 mediated inflammation before the development of a more complex, multi-cytokine dysregulated state due to advanced COVID-19 and/or complicating bacterial sepsis. We did not measure IL-6 levels as this was an urgent compassionate access program rather than an exploratory clinical trial.

For clinical trials of new treatments to have the best chance of demonstrating a significant effect, selection of appropriate population and outcome markers is crucial. We propose that evidence of hyperinflammation should define the population for IL-6 receptor blockade. Our careful description identifies temperature and CRP at 48 hours, oxygen requirements at seven days and WHO ordinal scale at 15 days as useful markers of response and can help estimate effect size. Compassionate use case series such as ours, if carefully conducted and reported, can contribute to the overall evidence base and support the design of randomised controlled trials.

Acknowledgements

DF is acting as a principle investigator for a Roche sponsored trial. JL has consulted for Roche without remuneration

1. Mehta P, McAuley DF, Brown M, Sanchez E, Tattersall RS, Manson JJ et al. COVID-19: consider cytokine storm syndromes and immunosuppression. Lancet. 2020;395(10229):1033-4.

2. Qin C, Zhou L, Hu Z, Zhang S, Yang S, Tao Y et al. Dysregulation of immune response in patients with COVID-19 in Wuhan, China. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America. 2020;10.1093/cid/ciaa248.

3. Giamarellos-Bourboulis EJ, Netea MG, Rovina N, Akinosoglou K, Antoniadou A, Antonakos N et al. Complex Immune Dysregulation in COVID-19 Patients with Severe Respiratory Failure. Cell Host Microbe. 2020;10.1016/j.chom.2020.04.009.

4. Xu X, Han M, Li T, Sun W, Wang D, Fu B et al. Effective treatment of severe COVID-19 patients with tocilizumab. Proc Natl Acad Sci U S A. 2020;10.1073/pnas.2005615117.

5. Regeneron and Sanofi Provide Update on U.S. Phase 2/3 Adaptive-Designed Trial of Kevzara® (sarilumab) in Hospitalized COVID-19 Patients [press release]. 27/04/2020 2020.

6. Tocilizumab improves significantly clinical outcomes of patients with moderate or severe COVID-19 pneumonia [press release]. 27.04.2020 2020.

7. ICNARC. [Available from: <https://www.icnarc.org/Our-Audit/Audits/Cmp/Reports>.

8. WHO. Off-label use of medicines for COVID-19. [Available from: <https://www.who.int/news-room/commentaries/detail/off-label-use-of-medicines-for-covid-19>.

9. Ruan Q, Yang K, Wang W, Jiang L, Song J. Clinical predictors of mortality due to COVID-19 based on an analysis of data of 150 patients from Wuhan, China. Intensive Care Med. 2020;10.1007/s00134-020-05991-x.

10. Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet. 2020;395(10229):1054-62.

11. Kotch C, Barrett D, Teachey DT. Tocilizumab for the treatment of chimeric antigen receptor T cell-induced cytokine release syndrome. Expert Rev Clin Immunol. 2019;15(8):813-22.

12. FDA. Actemra (tocilizumab) injection label [Available from: <https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/125276s092lbl.pdf>.

13. Pepys MB, Hirschfield GM. C-reactive protein: a critical update. J Clin Invest. 2003;111(12):1805-12.

14. Worwood M. Indicators of the iron status of populations: ferritin [Available from: <https://www.who.int/nutrition/publications/micronutrients/anaemia_iron_deficiency/9789241596107_annex2.pdf>.

Figure 1

Lines represent values for individual patients before and after tocilizumab dosing. Grey lines, ward-based patients; black lines, intensive care patients; solid lines, survivors; dotted, patients who died. Letters identify individual patients for comparison across panels. Values are shown for **A)** C-reactive protein; **B)** maximum daily temperature; **C)** mean daily oxygen flow rate for ward patients; **D)** mean daily PaO2 (kPa):FiO2 (%) ratio for ICU patients; and **E)** WHO ordinal scale for clinical improvement on days before and after the first dose of tocilizumab. Plasma C-reactive protein was 311 (138-332) mg/L on the day leading up to tocilizumab treatment and fell to 218 (151-332) mg/L and 110 (58-184) mg/L respectively on the first and second days after treatment (p=0·001 (Friedman test)). Over 1 week, mean PaO2:FiO2 ratios improved in intensive care patients by 41% [95% CI 11 to 70] and mean oxygen flow rates fell in ward patients by 69% [95% CI 36 to 102].